ResultsIQ

ResultsIQ › Latest results › Medplus Health Services Limited

Medplus Health Services Limited Q1 FY27 results deck summary

NSE: MEDPLUS · BSE: 543427

Results deck of 21 Jul 2026, summarised by AI from the filing.

Q1 FY27 revenue rose 21.8% to ₹18,796 million but operating EBITDA margin fell to 3.5%.

Key takeaways

  1. Revenue Q1 FY27 revenue ₹18,796 million, up 21.8% from ₹15,426 million in Q1 FY26.
  2. Margin Gross margin fell 160 bps to 24.5% and operating EBITDA margin fell 120 bps to 3.5%.
  3. Margin pressure Lower private label sales mix and lower franchisee margin reduced pharmacy gross margin.

Original filing on BSE

Medplus Health Services Limited Q1 FY27 results

As filed: Revenue ₹1,880 cr (+22% year on year), EBITDA ₹133 cr (+2% year on year), PAT ₹33.2 cr (−21% year on year), EBITDA margin 7.1% (−140 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,864 cr (+23% year on year), EBITDA ₹169 cr (+24% year on year), PAT ₹64.0 cr (+25% year on year), EBITDA margin 9.1% (+7 bps). Score 57 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were below it. EBITDA margin was flat year on year. Other income 26% of PBT. Profit rose ₹13.0 cr on a year ago, against ₹17.0 cr the year before. Share price after the results: −1.9% in 30 days (Nifty 500: −2.5%).
  • Q3 FY26: Revenue ₹1,806 cr (+16% year on year), EBITDA ₹159 cr (+20% year on year), PAT ₹57.8 cr (+26% year on year), EBITDA margin 8.8% (+33 bps). Score 43 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was well below it; profit growth was below it. EBITDA margin rose 33 bps year on year. Share price after the results: +3.1% in 28 days (Nifty 500: +0.4%).
  • Q2 FY26: Revenue ₹1,679 cr (+7% year on year), EBITDA ₹150 cr (+21% year on year), PAT ₹56.0 cr (+44% year on year), EBITDA margin 8.9% (+107 bps). Score 30 of 100, Below trend. Revenue and profit growth were below the company's own trend; EBITDA growth was well below it. EBITDA margin rose 107 bps year on year. Share price after the results: +6.0% in 28 days (Nifty 500: +0.9%).
  • Q1 FY26: Revenue ₹1,543 cr (+4% year on year), EBITDA ₹131 cr (+39% year on year), PAT ₹42.0 cr (+200% year on year), EBITDA margin 8.5% (+218 bps). Score 53 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was well above it; profit growth was above it. EBITDA margin rose 218 bps year on year. Other income 28% of PBT. Profit fell 18% from last quarter. Profit rose ₹28.0 cr on a year ago, more than the ₹10.0 cr it added the year before. Share price after the results: −9.0% in 30 days (Nifty 500: +0.2%).
  • Q4 FY25: Revenue ₹1,510 cr (+1% year on year), EBITDA ₹136 cr (+28% year on year), PAT ₹51.0 cr (+50% year on year), EBITDA margin 9.0% (+190 bps). Score 45 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 190 bps year on year. Other income 26% of PBT. Revenue fell 3% from last quarter. Revenue rose ₹19.0 cr on a year ago, against ₹238 cr the year before. Share price after the results: −4.9% in 30 days (Nifty 500: +3.1%).
  • Q3 FY25: Revenue ₹1,561 cr (+8% year on year), EBITDA ₹132 cr (+43% year on year), PAT ₹46.0 cr (+229% year on year), EBITDA margin 8.5% (+207 bps). Score 76 of 100, Above trend. EBITDA margin rose 207 bps year on year. Not enough history for a trend yet: scored on growth alone.
  • Q2 FY25: Revenue ₹1,576 cr, EBITDA ₹124 cr, PAT ₹39.0 cr, EBITDA margin 7.9%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,576 cr). Scored once a year-earlier consolidated quarter exists.

Past price moves after results do not indicate future moves. Not a recommendation.

Medplus Health Services Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.